Introduction {#s1}
============

Chronic obstructive pulmonary disease (COPD) is the major cause of mortality and morbidity in the USA and growing cause of chronic disease globally. The current pharmacological therapies for COPD, such as corticosteroids and β2 agonists, may provide symptom relief, reduce the rate of exacerbations, hospitalisations and possibly mortality, but despite this, many patients still experience symptoms, exacerbations and disease progression. Although the exact cellular mechanisms underlying COPD pathogenesis are not completely understood, the consensus is that oxidative stress and inflammation induced by exposure to cigarette smoke or other environmental or occupational hazards are responsible for development of COPD.[@R1] Therefore, a neutraceutical with potent antioxidant and anti-inflammatory properties and relatively few side effects could be an attractive treatment option for COPD.

Quercetin (3,3′,4′,5,7-pentahydroxyflavone) is a dietary flavonoid and has potent antioxidant and anti-inflammatory properties. We have demonstrated that oral treatment with a low dose of quercetin decreases inflammation, oxidative stress and matrix metalloproteinase production in a mouse model of COPD.[@R2] Quercetin supplemented diet also alleviates rhinovirus-induced lung inflammation in mice with COPD phenotype.[@R3] Recent studies have also demonstrated amelioration of hyperglycaemia, reduction of blood pressure and improvement of cardiovascular health by inhibiting platelet aggregation in experimental models.

Accumulating epidemiological evidence suggests that quercetin-rich diets are associated with lower incidence of asthma[@R4] and reduce disease severity in subjects with COPD.[@R5] Treatment with quercetin decreased markers of oxidative stress and inflammation in plasma of patients with pulmonary sarcoidosis, another chronic lung inflammatory disease driven by oxidative stress.[@R6] In another study, quercetin was shown to reduce blood pressure and plasma lipids in overweight or obese subjects with a high cardiovascular disease risk.[@R8] Daily intake of quercetin-rich onion peel extract (equivalent to 100 mg of quercetin/day) for 10 weeks decreased blood pressure, serum lipids and blood glucose levels in male smokers.[@R9] Additionally, treatment with quercetin for 12 weeks reduced the risk of acquiring upper respiratory infection in a large population of healthy adults.[@R10] The latter study also suggests that quercetin treatment in healthy volunteers has no adverse effects. Furthermore, a meta-analysis of randomised controlled trials indicated treatment with quercetin reduces plasma C reactive protein[@R11] and blood pressure in hypertensive subjects.[@R12] Despite these epidemiological and experimental pieces of evidence, there have been no clinical trials examining the therapeutic effects of quercetin in COPD. An objective of this study was to determine the safety of quercetin supplementation in patients with COPD, because it is the first step towards using quercetin as a therapeutic agent in these patients.

Materials and methods {#s2}
=====================

Clinical trial registration {#s2-1}
---------------------------

This safety study was a randomised, double-blind, placebo-controlled, single-centre dose-escalation phase I clinical trial registered with ClinicalTrials.gov. It is a single-centre study conducted at the University of Michigan.

Study drug {#s2-2}
----------

Quercetin and placebo were supplied by Quercegen Pharmceuticals (Sudbury, Massachusetts, USA) as orange-flavoured soft chews. Quercetin chews consisted 500 mg of quercetin, 325 mg of vitamin C and 10 mg vitamin B~3~. Placebo formulation contained vitamin C and vitamin B~3~ in the same proportion as quercetin chews.

Patient enrolment and study design {#s2-3}
----------------------------------

All subjects were recruited from the University of Michigan Pulmonary Clinic. Patients with COPD with mild-to-moderate lung disease with forced expiratory volume in one second (FEV~1~):forced vital capacity ratio of \<0.7 and a per cent predicted FEV~1~ of \>35% and \<80% as determined by postbronchodilator spirometry were recruited for the study. All subjects had a smoking history of 10 pack-years or more and ceased to smoke for at least 2 months at the time of recruitment. Out of 12 recruited subjects with COPD, 10 eligible subjects between the ages of 40 and 80 years were enrolled ([table 1](#T1){ref-type="table"}). One subject dropped out because he was unable to come to study visits after being determined to be eligible and therefore was not randomised.

###### 

Patient cohort and treatment

  Patient number   Race                                          Age   Sex   \% FEV~1~   FEV~1~/FVC   Treatment
  ---------------- --------------------------------------------- ----- ----- ----------- ------------ -----------
  1                Caucasian                                     76    F     79.9        80.6         500
  2                Caucasian and Alaska Native/American Indian   60    M     55.5        67.6         500
  3                Caucasian                                     63    F     37.0        63.0         Placebo
  4                Caucasian                                     58    M     51.2        86.3         1000
  5                Caucasian                                     77    F     38.4        63.6         Placebo
  6                Caucasian                                     78    M     50.2        49.9         1000
  7                Caucasian                                     67    F     57.1        64.2         2000
  8                Caucasian                                     62    M     45.4        68.8         Placebo
  9                Caucasian                                     72    M     48.8        52.9         2000

F, female; FEV~1~, forced expiratory volume in one second; FVC, forced vital capacity; M, male.

Enrolled subjects were divided into three cohorts, with three subjects in each cohort. In each cohort, one subject was allocated to placebo and the other two subjects to one of the three doses of quercetin (500, 1000 or 2000 mg/day) as per the randomisation codes that were generated by a biostatistician prior to subject enrolment. The study design involved dose escalation in separate cohorts. Subjects in cohort 1 were treated with 500 mg quercetin; those in cohort 2 were treated with 1000 mg; and those in cohort 3 were treated with 2000 mg/day. The safety of quercetin treatment was assessed at low dose prior to treating subjects in another cohort with the next higher dose. All subjects avoided quercetin-rich diets for 7 days prior to (run-in period) and during quercetin therapy. Subjects in each cohort were treated with placebo or quercetin orally for 7 days. The study subjects took the study drug twice a day, along with food, and maintained a study drug log. Study drugs were provided for three extra days, and therefore, the remaining study drugs were collected from the subjects at the end of the study period. Compliance was determined on the basis of the study drug log and by counting the remaining study drug chews. Blood was collected and spirometry was performed at the run-in period and at the end of 1-week treatment with the study drug. Safety was determined by assessing postbronchodilator FEV~1~, blood profile (complete blood count and comprehensive metabolic panel) and patient-reported adverse events. Due to small number of subjects in each arm, we were not able to perform statistical analysis.

Patient and public involvement {#s2-4}
------------------------------

This study involved participation of a COPD population. Informed consent with study details was obtained from patients, and the written consent was obtained from each enrolled subject. Patients recorded symptoms daily in 'COPD Assessment Test', a standardised questionnaire. Abnormal laboratory results and the patient-reported symptoms were reviewed by the clinical principal investigator to determine the severity of the abnormality and the casuality of the study participation. The clinical investigator informed the participants if the abnormalities were clinically significant.

Results and discussion {#s3}
======================

Subjects showed 100% compliance. There were no serious adverse events or substantial changes in complete blood count and lung function in any of the groups ([table 2](#T2){ref-type="table"}). All the patients showed parameters of liver and kidney functions within the range at run-in and post-treatment (data not shown). Interestingly, five out of six patients assigned to quercetin group had higher than normal fasting blood glucose levels at run-in. Three out of five subjects showed reduced blood sugar levels after quercetin treatment, irrespective of the quercetin dose. Unfortunately, none of the subjects in the placebo group had higher than normal fasting blood glucose levels, and therefore it is not possible to predict whether this effect is due to quercetin. Since we did not expect any changes to occur in blood sugar levels following quercetin treatment, we did not consider distribution of subjects with high blood glucose levels in both the placebo and quercetin groups during randomisation. Patient-reported adverse events were gastro-oesophageal reflux disease (GERD), stomach upset, breathlessness, chest congestion, headache and nausea. None of these events were determined to be study drug-related except in two subjects, one in the placebo group and the other one in the 500 mg quercetin dosing group. Both subjects reported symptoms of GERD, and the subject in the placebo group needed treatment to reduce the GERD symptoms. Taken together, these results indicate that subjects with COPD safely tolerated up to 2000 mg/day quercetin. However, the limitations of this trial are the small sample size and the short duration of treatment period with the study drug. Therefore, the safety of quercetin should be confirmed in a large cohort of patients and after prolonged treatment with quercetin, that is, for at least 6 months.

###### 

Effect of quercetin on lung function and blood counts and blood glucose levels

  Treatment     FEV~1~   FEV~1~/FVC   WBC (K/mL)   Platelets (K/mL   Fasting glucose (mg/dL)                            
  ------------- -------- ------------ ------------ ----------------- ------------------------- ------ ----- ----- ----- -----
  Placebo       38.8     35.0         51.0         63.6              5.4                       6.4    236   223   90    99
  Placebo       40.9     40.3         63.6         63.3              5.5                       4.6    170   167   89    126
  Placebo       53.3     50.7         70.6         74.6              5.6                       5.8    135   130   111   84
  500 mg/day    75.7     79.3         79.8         82.4              5                         5      259   266   89    98
  500 mg/day    46.7     43.2         66.8         63.9              10.6                      11.1   236   268   138   89
  1000 mg/day   53.0     47.3         89.0         92.5              6.2                       5.5    144   153   122   125
  1000 mg/day   49.5     50.5         53.1         49.9              5.5                       4.6    164   178   234   139
  2000 mg/day   53.9     55.5         67.1         66.0              8.3                       8.3    280   298   143   140
  2000 mg/day   50.0     47.3         52.0         56.4              5.7                       5.3    271   277   150   91

FEV~1~, forced expiratory volume in one second; FVC, forced vital capacity; WBC, white blood cell.
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